Actinium Pharmaceuticals Stock Today
| ATNM Stock | USD 1.15 0.02 1.71% |
PerformanceVery Weak
| Odds Of DistressLow
|
Actinium Pharmaceuticals is selling at 1.15 as of the 26th of February 2025; that is 1.71 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.12. Actinium Pharmaceuticals has less than a 16 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. The company was incorporated in 2000 and is based in New York, New York. The company has 31.2 M outstanding shares of which 2.02 M shares are presently shorted by private and institutional investors with about 8.81 trading days to cover. More on Actinium Pharmaceuticals
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Actinium Stock Highlights
| Chairman CEO | MS MBA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Actinium Pharmaceuticals (ATNM) is traded on NYSE MKT Exchange in USA. It is located in 100 Park Avenue, New York, NY, United States, 10017 and employs 37 people. Actinium Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.5 M. Actinium Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 31.2 M outstanding shares of which 2.02 M shares are presently shorted by private and institutional investors with about 8.81 trading days to cover.
Actinium Pharmaceuticals currently holds about 116.33 M in cash with (47.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Actinium Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationActinium Pharmaceuticals holds a total of 31.2 Million outstanding shares. Almost 68.57 percent of Actinium Pharmaceuticals outstanding shares are held by general public with 1.78 (percent) owned by insiders and only 29.65 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Actinium Ownership Details
Actinium Pharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Actinium Pharmaceuticals market risk premium is the additional return an investor will receive from holding Actinium Pharmaceuticals long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.26) | |||
| Total Risk Alpha | (0.29) | |||
| Treynor Ratio | (0.26) |
Actinium Stock Against Markets
Actinium Pharmaceuticals Corporate Management
| Bernie PMP | Executive Management | Profile | |
| Qing Liang | VP Sciences | Profile | |
| Madhuri MD | Vice Therapy | Profile | |
| Lynn MBA | Chief Officer | Profile | |
| Paul Esq | Vice Counsel | Profile | |
| Jenny Hsieh | Chief Officer | Profile | |
| Dr MS | VP Operations | Profile |
Already Invested in Actinium Pharmaceuticals?
The danger of trading Actinium Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Actinium Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Actinium Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Actinium Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Actinium Pharmaceuticals is a strong investment it is important to analyze Actinium Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Actinium Pharmaceuticals' future performance. For an informed investment choice regarding Actinium Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.